D.H.E.
Brand names,
D.H.E.
Analogs
D.H.E.
Brand Names Mixture
D.H.E.
Chemical_Formula
C33H37N5O5
D.H.E.
RX_link
http://www.rxlist.com/cgi/generic2/dihyergmes.htm
D.H.E.
fda sheet
D.H.E.
msds (material safety sheet)
D.H.E.
Synthesis Reference
No information avaliable
D.H.E.
Molecular Weight
583.678 g/mol
D.H.E.
Melting Point
No information avaliable
D.H.E.
H2O Solubility
No information avaliable
D.H.E.
State
Solid
D.H.E.
LogP
No information avaliable
D.H.E.
Dosage Forms
Liquid
D.H.E.
Indication
For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
D.H.E.
Pharmacology
Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
D.H.E.
Absorption
Interpatient variable and may be dependent on the administration technique
D.H.E.
side effects and Toxicity
Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
D.H.E.
Patient Information
PATIENT INFORMATIOn
Follow the link below to get detailed information before taking D.H.E. 45� (dihydroergotamine mesylate) Injection.
http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm
D.H.E.
Organisms Affected
Humans and other mammals